Ventricular Remodeling Therapies focus on reversing or stabilising structural and functional changes that occur in the ventricles following myocardial injury, pressure overload, volume overload or chronic cardiomyopathy. As heart failure continues to rise globally, clinicians increasingly seek comprehensive updates on Ventricular Remodeling Therapies when attending heart-failure and interventional tracks at a cardiology conference. With the expanding availability of pharmacologic, device-based and biologically engineered treatments, this session delivers a deep exploration of ventricular structural-recovery strategies that shape modern care.

The session begins by outlining the mechanisms of ventricular remodeling, including myocyte hypertrophy, fibrosis, extracellular-matrix expansion, inflammatory activation, altered calcium handling and geometric distortion. Participants learn how remodeling contributes to declining ejection fraction, progressive dilation, increased wall stress and arrhythmia risk.

Therapeutic options are reviewed across three major domains. Pharmacologic therapies include RAAS inhibitors, beta-blockers, ARNIs, SGLT2 inhibitors, mineralocorticoid antagonists and antifibrotic investigational agents. Participants explore how each class modulates neurohormonal pathways and promotes reverse remodeling.

Device-based solutions address mechanical and electrical contributors to remodeling. The session covers CRT, LVAD support, baroreflex activation, neuromodulation therapies and pressure-sensing implants. Case discussions illustrate patient selection, response prediction and device-optimisation approaches.

Biologic and regenerative therapies represent a growing frontier. Attendees learn about stem-cell strategies, gene-modulation therapies, RNA platforms, engineered tissues and molecular approaches targeting fibrosis resolution and myocardial regeneration.

Imaging plays a pivotal role in monitoring therapeutic response. Participants examine how echocardiography, strain imaging, MRI and molecular tracers quantify volumes, fibrosis burden, viability and geometric improvement.

Future directions include AI-based response prediction, precision-therapeutic matching, biomarker-guided treatment sequencing and hybrid therapy combinations. By integrating pharmacologic, mechanical and biological interventions, clinicians gain a comprehensive framework for improving ventricular function and reducing heart-failure progression.